• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组中的突变:变体的出现及其对疫苗的影响]

[Mutations in the SARS-CoV-2 genome: the emergence of variants and the impact on vaccines].

作者信息

Worp Nathalie, Koopmans Marion P G, Fouchier Ron A M, Oude Munnink Bas B

机构信息

Erasmus MC, afd. Viroscience, Rotterdam.

Contact: Bas B. Oude Munnink (

出版信息

Ned Tijdschr Geneeskd. 2021 Nov 30;165:D6496.

PMID:35138744
Abstract

Almost two years after the introduction of SARS-CoV-2, it has become clear that the virus is unlikely to disappear any time soon. It is also clear that the virus mutates, resulting in specific variants of SARS-CoV-2. The exact implications of these variants are being investigated but it is likely that they have a selective advantage over previously circulating variants. It is possible that SARS-CoV-2 will mutate in the coming years to such an extent that existing vaccines do not offer sufficient protection against hospitalizations in the general population. At present, the protection of current vaccines against infection is observed to be reduced by the emergence of variants but remains high against hospitalizations and severe disease. Booster vaccinations are currently advised for specific risk groups where the regular vaccination schedule leads to an insufficient immune response, and are being considered for people in old age where the vaccine effectiveness is lower.

摘要

在新型冠状病毒(SARS-CoV-2)出现近两年后,情况已很明显,该病毒短期内不太可能消失。同样明显的是,该病毒会发生变异,从而产生SARS-CoV-2的特定变体。这些变体的确切影响正在研究中,但它们可能比先前传播的变体具有选择性优势。未来几年,SARS-CoV-2有可能发生极大程度的变异,以至于现有疫苗无法为普通人群提供足够的住院防护。目前观察到,变体的出现降低了现有疫苗对感染的防护效果,但对住院和重症疾病仍有很高的防护作用。目前建议针对常规疫苗接种方案导致免疫反应不足的特定风险群体进行加强接种,并正在考虑为疫苗效力较低的老年人进行加强接种。

相似文献

1
[Mutations in the SARS-CoV-2 genome: the emergence of variants and the impact on vaccines].[严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组中的突变:变体的出现及其对疫苗的影响]
Ned Tijdschr Geneeskd. 2021 Nov 30;165:D6496.
2
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.既往感染与疫苗接种产生针对 SARS-CoV-2 变异株的中和抗体效力。
mBio. 2021 Dec 21;12(6):e0265621. doi: 10.1128/mBio.02656-21. Epub 2021 Dec 7.
3
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
4
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2(Delta)变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络,2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
5
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.针对 SARS-CoV-2 及其变体的多样化疫苗平台。
Expert Rev Vaccines. 2022 Jan;21(1):47-67. doi: 10.1080/14760584.2022.1997601. Epub 2022 Jan 11.
6
Omicron: Call for updated vaccines.奥密克戎:呼吁更新疫苗。
J Med Virol. 2022 Apr;94(4):1261-1263. doi: 10.1002/jmv.27530. Epub 2021 Dec 28.
7
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
8
Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.2021 年初全球 COVID-19 大流行期间,低和高疫苗接种率国家中 SARS-CoV-2 变体的单倍型分布。
Infect Genet Evol. 2022 Jan;97:105164. doi: 10.1016/j.meegid.2021.105164. Epub 2021 Nov 27.
9
Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.预测的表位丰度支持针对 SARS-CoV-2 关切变异株的疫苗诱导的细胞毒性保护。
Front Immunol. 2021 Nov 25;12:732693. doi: 10.3389/fimmu.2021.732693. eCollection 2021.
10
The COVID-19 pandemic: viral variants and vaccine efficacy.新型冠状病毒肺炎大流行:病毒变异株与疫苗效力。
Crit Rev Clin Lab Sci. 2022 Jan;59(1):66-75. doi: 10.1080/10408363.2021.1979462. Epub 2021 Oct 1.